- Cintas Corporation (NASDAQ:CTAS) reported second-quarter FY23 sales growth of 13% year-on-year to $2.17 billion, beating the consensus of $2.13 billion.
- Organic revenue growth rate was 12.8% for the quarter.
- Gross margin expanded by 100 basis points Y/Y to 47% in the quarter.
- Selling and administrative expenses were $577.5 million. Operating income increased 16.7% to $444.9 million, while the operating margin expanded by 70 basis points to 20.5%.
- EPS of $3.12 beat the analyst consensus of $3.03.
- The company held $89.8 million in cash and equivalents as of November 30, 2022. Net cash provided by operations for six months totaled $619.1 million, with a free cash flow of $472.7 million.
- Outlook: Cintas raised its annual revenue expectations from $8.58 billion – $8.67 billion to $8.67 billion – $8.75 billion, above the consensus of $8.63 billion.
- The company boosted the FY23 EPS outlook from $12.30 – $12.65 to $12.50 – $12.80 versus the consensus of $12.58.
- Price Action: CTAS shares are trading higher by 2.39% at $454.55 on the last check Wednesday.
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s
The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…
